Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9941609 | 1.00 | ESR1 (0.38) | ESR1ESR2 | |
| SCHEMBL4229838 | 0.83 | ESR1 (0.38) | ESR1ESR2 | |
| SCHEMBL2701262 | 0.81 | FUCA1 (0.37) | ESR1ESR2 | |
| SCHEMBL5907203 | 0.80 | APLNR (0.30) | — | |
| SCHEMBL17835247 | 0.77 | P2RX7 (0.32) | — | |
| SCHEMBL17835252 | 0.77 | P2RX7 (0.32) | — | |
| SCHEMBL17835249 | 0.77 | P2RX7 (0.32) | — | |
| SCHEMBL11046887 | 0.74 | ALDH1A1 (0.39) | ESR1ESR2 | |
| SCHEMBL24064819 | 0.73 | ESR1 (0.36) | ESR1ESR2 | |
| SCHEMBL19381561 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20140371260-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (GE) | 2014-12-18 | — | — | US | disclosed |
| US-20100227852-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-09-09 | — | — | US | disclosed |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-05-14 | — | — | US | disclosed |
| US-20070185151-A1 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-08-09 | — | — | US | disclosed |
| US-7238703-B2 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-07-03 | — | — | US | disclosed |
| US-7022729-B2 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-04 | — | — | US | disclosed |
| US-20060019982-A1 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-01-26 | — | — | US | disclosed |
| US-20060019983-A1 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-01-26 | — | — | US | disclosed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20040034055-A1 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371260-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, BACE1, CHRNE | ESR1 734/4885ESR2 702/4885 |
| US-20100227852-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | ACHE, BACE1, CHRNE | ESR1 734/4885ESR2 702/4885 |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | ESR1 1810/4885ESR2 1176/4885 |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | ESR1 1810/4885ESR2 1176/4885 |
| US-20070185151-A1 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists | GRIN3A, GRIN2A, HTR3A | ESR1 3879/4885ESR2 2986/4885 |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | ACHE, BACE1, BCHE | ESR1 876/4885ESR2 823/4885 |
| US-20060019983-A1 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists | GRIN3A, GRIN2A, HTR3A | ESR1 3706/4885ESR2 2779/4885 |
| US-20060019982-A1 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists | GRIN3A, GRIN2A, HTR3A | ESR1 3706/4885ESR2 2779/4885 |
| US-20040034055-A1 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists | GRIN3A, GRIN2A, HTR3A | ESR1 3785/4885ESR2 2892/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | ESR1 719/4885ESR2 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.